Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-90 SIRT + Durvalumab + Gemcitabine/Cisplatin in Advanced Intrahepatic Cholangiocarcinoma
NCT05655949Phase 2Recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Nanoparticles, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium-90, durvalumab in cholangiocarcinoma (CCA), sponsored by Beth Israel Deaconess Medical Center. Started Feb 2024; status: recruiting.
02
Drugs
yttrium-90durvalumab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05655949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05655949.